Article Versions Notes

Bruzzese A, Vigna E, Terzi D, Greco S, Martino EA, Vangeli V, Mendicino F, Lucia E, Olivito V, Labanca C, et al. Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura. Hematology Reports. 2023; 15(3):448-453. https://doi.org/10.3390/hematolrep15030046

Bruzzese, Antonella, Ernesto Vigna, Dario Terzi, Sonia Greco, Enrica Antonia Martino, Valeria Vangeli, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Caterina Labanca, and et al. 2023. "Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura" Hematology Reports 15, no. 3: 448-453. https://doi.org/10.3390/hematolrep15030046

Bruzzese, A., Vigna, E., Terzi, D., Greco, S., Martino, E. A., Vangeli, V., Mendicino, F., Lucia, E., Olivito, V., Labanca, C., Morelli, R., Neri, A., Morabito, F., Zinno, F., Mastroianni, A., & Gentile, M. (2023). Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura. Hematology Reports, 15(3), 448-453. https://doi.org/10.3390/hematolrep15030046